What does a payer want to see before approving mazdutide?

I have the plan documents and the written criteria, which took two calls to obtain.

I can find plenty of assertions about this and almost no reasoning, which is usually a sign that nobody has checked.

Assume no laboratory access beyond what I can pay a third party for.

Concretely, what should I do, and how would I know afterwards whether I did it right?

On the detail: prior authorisation is an adjudication against written criteria, and the criteria are usually obtainable. Requesting them before submitting is the single highest-yield step in the process.

503A and 503B differ in what they are permitted to do and what they must demonstrate. A 503A pharmacy compounds against individual prescriptions, is exempt from current good manufacturing practice requirements, and is regulated primarily at state level with USP chapter compliance as the operative standard. A 503B outsourcing facility registers federally, must comply with cGMP, may prepare without patient-specific prescriptions, and is subject to FDA inspection. The practical consequence is that a 503B preparation carries release testing and a 503A preparation generally does not.

It helps to be literal here: whether a telehealth prescription can be filled at a retail pharmacy depends on the prescription and the jurisdiction rather than on the modality: a prescription for a licensed product from a prescriber licensed in the patient’s jurisdiction is generally fillable anywhere that stocks it. A prescription written to a specific compounding pharmacy for a preparation only that pharmacy makes is not portable, and that non-portability is sometimes the commercial point.

Verify accreditation on the accreditor’s register rather than on the pharmacy’s website. It takes a minute.

Model the cost across the whole route, including the parts that are not the drug: consultation fees, laboratory monitoring, shipping, and the tests you will pay for yourself.

The salt-form point: the statutory pathway for compounding a copy of an approved drug during a shortage applies to the same active moiety as the approved product. A preparation described as a salt form — "semaglutide sodium", "semaglutide acetate" — is describing a different chemical entity from the approved base, and the description is usually there to construct an argument that it is not a copy. Whatever the legal merits, it means what is in the vial is not what was studied.

On the detail: features of a defensible telehealth intake: a real history including contraindications and family history, a recorded weight and height rather than a self-attested figure, baseline laboratory work or a documented reason for its absence, a named prescriber you can identify and verify, a titration plan, and a mechanism for reporting adverse events that reaches a clinician. A checkbox intake that issues a prescription in four minutes has none of these.

Model twelve months, not one. The fee structures are designed to be compared monthly.

A defensible telehealth encounter has identifiable features, and the absence of those features is the most useful signal available to a prospective patient.

What a payer wants in a prior authorisation is documentation mapped to their own written criteria, in their own terms: a diagnosis code, a documented body mass index or comorbidity meeting their threshold, a record of a supervised lifestyle intervention over their specified duration, and documentation of any step-therapy agent tried and its outcome. A clinical narrative that does not map onto those fields will be denied by someone who never reads the narrative.

USP General Chapter <797> on sterile preparation compounding sets the microbiological risk categories and default beyond-use dates that most compounded beyond-use dating in this space derives from.

Keep every document. The appeal you might need in six months is built from records you have to have kept now.

edited 19 Aug 2025 by n_takahashi — fixed an arithmetic slip in the third paragraph

Potency variation between compounders is a manufacturing-control question rather than an integrity question, and it is the predictable consequence of preparing a potent peptide by hand at small scale.

The internal-then-external appeal path is worth pursuing further than most people do, because the external reviewer is not the plan. Internal appeals are adjudicated by the entity that issued the denial; external review is conducted by an independent organisation against the same criteria, and it overturns a non-trivial fraction of denials.

The limitation of cost modelling is that it assumes a stable price environment, and the price environment in this category has been anything but stable.

If the intake did not ask about contraindications, that tells you what kind of service it is.

edited 6 Jun 2025 by syringe_ninety — tightened the wording; no substantive change